乳腺癌是女性最常見的惡性疾病之一,，三陰性乳腺癌與其他亞型相比，侵襲性和復(fù)發(fā)率較高,，并且尚無(wú)針對(duì)三陰性乳腺癌患者的有效靶點(diǎn)或個(gè)體化治療,。因此,，找到三陰性乳腺癌的有效預(yù)后標(biāo)志，有助于臨床醫(yī)師對(duì)患者進(jìn)行診療,。

　　2018年7月,，日本癌癥學(xué)會(huì)《癌癥科學(xué)》發(fā)表復(fù)旦大學(xué)附屬腫瘤醫(yī)院、福建醫(yī)科大學(xué)附屬協(xié)和醫(yī)院的研究報(bào)告,，發(fā)現(xiàn)了三陰性乳腺癌預(yù)后新標(biāo)志,。

　　首先，該研究通過(guò)組織微陣列對(duì)乳腺癌標(biāo)本的小分子核糖核酸-493（miR-493）表達(dá)水平進(jìn)行檢測(cè),，通過(guò)miR-493專用miRCURY LNA檢測(cè)探針進(jìn)行原位雜交檢測(cè),，染色結(jié)果由兩位獨(dú)立的病理科醫(yī)師復(fù)核，并且分為miR-493高表達(dá)或低表達(dá),。隨后,，通過(guò)生存曲線法和多因素風(fēng)險(xiǎn)比例回歸模型分析，明確miR-493與生存之間的相關(guān)性,。

　　結(jié)果發(fā)現(xiàn),，根據(jù)生存曲線分析，miR-493高表達(dá)患者與miR-493低表達(dá)患者相比,，無(wú)病生存較好,。對(duì)乳腺癌常見臨床病理因素進(jìn)行校正后，miR-493表達(dá)水平仍然是乳腺癌的重要預(yù)后因素,。進(jìn)一步亞型分析表明,，miR-493表達(dá)水平僅對(duì)三陰性乳腺癌患者預(yù)后顯著。根據(jù)國(guó)際乳腺癌分子分類學(xué)聯(lián)盟（METABRIC）數(shù)據(jù)庫(kù)總生存數(shù)據(jù),，這些結(jié)果得到驗(yàn)證,。

　　因此，該研究通過(guò)現(xiàn)有最大的乳腺癌組織微陣列之一證實(shí)了miR-493對(duì)三陰性乳腺癌的預(yù)后作用,，并且通過(guò)大型公開RNA測(cè)序數(shù)據(jù)庫(kù)對(duì)其進(jìn)行了驗(yàn)證,。

Cancer Sci. 2018 Jul;109(7):2294-2301.

MicroRNA-493 is a prognostic factor in triple-negative breast cancer.

Yao L, Liu Y, Cao Z, Li J, Huang Y, Hu X, Shao Z.

Fudan University Shanghai Cancer Center, Shanghai, China; Affiliated Union Hospital, Fujian Medical University, Fuzhou, China.

Breast cancer is one of the most common malignant diseases in women. Triple-negative breast cancer (TNBC) shows higher aggressiveness and recurrence rates than other subtypes, and there are no effective targets or tailored treatments for TNBC patients. Thus, finding effective prognostic markers for TNBC could help clinicians in their ability to care for their patients. We used tissue microarrays (TMAs) to detect microRNA-493 (miR-493) expression in breast cancer samples. A miRCURY LNA detection probe specific for miR-493 was used in in situ hybridization assays. Staining results were reviewed by two independent pathologists and classified as high or low expression of miR-493. Kaplan-Meier survival plots and multivariate Cox analysis were carried out to clarify the relationship between miR-493 and survival. In the Kaplan-Meier analysis, patients with high miR-493 expression had better disease-free survival than patients with low miR-493 expression. After adjusting for common clinicopathological factors in breast cancer, the expression level of miR-493 was still a significant prognostic factor in breast cancer. Further subtype analysis revealed that miR-493 expression levels were only significantly prognostic in TNBC patients. These results were validated in the Molecular Taxonomy of Breast Cancer International Consortium database for overall survival. We proved the prognostic role of miR-493 in TNBC by using one of the largest breast cancer TMAs available and validated it in a large public RNA sequencing database.

KEYWORDS: DFS; breast cancer; microRNA 493; prognostic factor; triple-negative

PMID: 29777630

PMCID: PMC6029816

DOI: 10.1111/cas.13644